Rating scales for assessing clinical added benefit or improvement

From the 35 identified drugs, 10 (29%) showed different decisions by HAS and G-BA, and only 2 (6%) showed a major difference between outcomes (Table 2)

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.